DDrare: Database of Drug Development for Rare Diseases

Acalabrutinib (DrugBank: Acalabrutinib)

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
61	Autoimmune hemolytic anemia	1

46. Malignant rheumatoid arthritis [ 4,183 clinical trials, 2,538 drugs, (DrugBank: 401 drugs), 183 drug target genes, 219 drug target pathways]

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 4,183 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02387762 (ClinicalTrials.gov)	April 2015	1/3/2015	ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate	A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate	Rheumatoid Arthritis	Drug: acalabrutinib;Drug: Placebo	Acerta Pharma BV	NULL	Completed	18 Years	75 Years	All	31	Phase 2	United States

61. Autoimmune hemolytic anemia [ 90 clinical trials, 72 drugs, (DrugBank: 23 drugs), 19 drug target genes, 147 drug target pathways]

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 90 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04657094 (ClinicalTrials.gov)	December 10, 2020	1/12/2020	Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia	A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia	Autoimmune Hemolytic Anemia;Chronic Lymphocytic Leukemia;Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;Warm Antibody Autoimmune Hemolytic Anemia	Drug: Acalabrutinib	City of Hope Medical Center	National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	22	Phase 2	United States